Metabolic syndrome and its potential effect on treatment response to aripiprazole: A post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010)

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 631-634

  Kemp, David E ^a   Eudicone, James M ^b   McQuade, Robert D ^c   Chambers, Jessie S ^b   Baker, Ross A ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE;

BIPOLAR DISORDER; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; LONG TERM CARE; METABOLIC SYNDROME X; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; METABOLIC SYNDROME X; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957286176     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181f0569f     Document Type: Letter

References (12)

1. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296: 1286-1289. (Pubitemid 44394901)
2. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry. 2009;66: 128-133.
3. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7: 424-430. (Pubitemid 41419409)
4. Fagiolini A, Frank E, Turkin S, et al. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry. 2008;69: 678-679. (Pubitemid 351792348)
5. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166: 345-353.
6. Richter N, Juckel G, Assion HJ. Metabolic syndrome: a follow-up study of acute depressive inpatients. Eur Arch Psychiatry Clin Neurosci. 2010;260: 41-49.
7. Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-Week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67: 626-637. (Pubitemid 43764240)
8. Kemp D, Calabrese J, Tran Q, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder. J Clin Psychiatry. 2010; doi: 10.4088/JCP.09m05159gre. Epub ahead of print.
9. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112: 2735-2752. (Pubitemid 41532612)
10. Keck PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007;68: 1480-1491.
11. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008; 69: 1046-1056.
12. Carroll JF, Chiapa AL, Rodriquez M, et al. Visceral fat, waist circumference, and BMI: impact of race/ethnicity. Obesity (Silver Spring). 2008;16: 600-607. (Pubitemid 351337456)